A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

STATUS

Recruiting
End date

Nov 10, 2024
participants needed

20
sponsor

Marcela V. Maus, M.D.,Ph.D.

Send

Updated on 10 November 2021

See if I qualify

platelet count

lymphoma

hodgkin's disease

absolute neutrophil count

ejection fraction

anakinra

measurable disease

pleural effusion

gilbert's syndrome

leukapheresis

pembrolizumab

nivolumab

ipilimumab

follicular lymphoma

diffuse large b-cell lymphoma

b-cell lymphoma

alt/ast

large b-cell lymphoma

refractory non-hodgkin's lymphoma

nervous system disorder

non-hodgkin's lymphoma refractory

Summary

This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL).

Relapsed NHL is the condition of returned Non-Hodgkin lymphoma.
Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma.
Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash.
Neurologic toxicity is nervous system disorder characterized by confusion

This research study involves two drugs:

Anakinra
Axicabtagene Ciloleucel.

Description

This Phase 2, single center, open-label research study is studying the combination of Anakinra and Axicabtagene Ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities in people with relapsed or refractory Non-Hodgkin lymphoma (NHL).

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

This research study involves two drugs:
Anakinra
Axicabtagene Ciloleucel
A total of 20 participants will be enrolled to this trial
The U.S. Food and Drug Administration (FDA) has not approved anakinra for use in treatment of Non-Hodgkin lymphoma (NHL).

Details

Condition	Sun Poisoning, Lymphoma, Refractory Non Hodgkin Lymphoma, nervous system disorder, non-hodgkin's lymphoma (nhl), Toxic encephalopathy, Non-Hodgkin's Lymphoma, neurotoxicity, Cytokine Release Syndrome, neurotoxic effect, Relapsed Non Hodgkin Lymphoma, Neurologic Disorders, Poisoning
Treatment	Anakinra, Axicabtagene Ciloleucel
Clinical Study Identifier	NCT04150913
Sponsor	Marcela V. Maus, M.D.,Ph.D.
Last Modified on	10 November 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
	At least 1 measurable lesion according to the revised IWG Response Criteria for Malignant Lymphoma 1. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
	At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy however steroids only require a 7-day washout. At least 3 half-lives must have elapsed from any prior systemic inhibitory/stimulatory immune checkpoint molecule therapy at the time the subject is planned for leukapheresis (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc)
	Toxicities due to prior therapy must be stable and recovered to Grade 1 (except for clinically non-significant toxicities such as alopecia)
	Age 18 or older
	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
	ANC 1000/uL
	Platelet count 75,000/uL
	Absolute lymphocyte count 100/uL
	Adequate renal, hepatic, pulmonary and cardiac function defined as
	Creatinine clearance (as estimated by Cockcroft Gault) 60 mL/min
	Serum ALT/AST 2.5 ULN
	Total bilirubin 1.5 mg/dl, except in subjects with Gilbert's syndrome
	Cardiac ejection fraction 50%, no clinically significant pericardial effusion, and no clinically significant ECG findings
	No clinically significant pleural effusion
	Baseline oxygen saturation >92% on room air
	Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential) Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
	History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years
	History of Richter's transformation of CLL
	Autologous stem cell transplant within 6 weeks of planned axicabtagene ciloleucel infusion
	History of allogeneic stem cell transplantation
	Prior CD19 targeted therapy with the exception of subjects who received axicabtagene ciloleucel in this study and are eligible for re-treatment
	Prior chimeric antigen receptor therapy or other genetically modified T cell therapy
	History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
	Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management
	History of HIV infection or acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines
	Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted
	Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of CNS lymphoma or primary CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases
	History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
	Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
	History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
	Expected or possible requirement for urgent therapy within 6 weeks due to ongoing or impending oncologic emergency (eg, tumor mass effect, tumor lysis syndrome)
	Primary immunodeficiency
	History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
	Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
	History of severe immediate hypersensitivity reaction to any of the agents used in this study
	Live vaccine 6 weeks prior to planned start of conditioning regimen
	Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential
	Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of axicabtagene ciloleucel
	In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
	History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

platelet count

lymphoma

hodgkin's disease

absolute neutrophil count

diffuse large b-cell lymphoma

b-cell lymphoma

alt/ast

large b-cell lymphoma

refractory non-hodgkin's lymphoma

nervous system disorder

non-hodgkin's lymphoma refractory

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity